SCHEMBL694089

SCHEMBL694089

Fc1ccc(-c2cc3[c]cccc3[nH]2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSV O60911 1/20 0.50
CTSL P07711 1/20 0.50
KDM4E B2RXH2 4/20 0.39
HPGD P15428 3/20 0.39
LMNA P02545 2/20 0.39
ALDH1A1 P00352 2/20 0.39
CCNB2 O95067 1/20 0.38
CDK1 P06493 1/20 0.38
CCNB1 P14635 1/20 0.38
GSK3A P49840 1/20 0.38
GSK3B P49841 1/20 0.38
CDK5 Q00535 1/20 0.38
CDK5R1 Q15078 1/20 0.38
CCNB3 Q8WWL7 1/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
NPC1 O15118 3/20 0.37
RAB9A P51151 3/20 0.37
MAPT P10636 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9853649 0.76 AOC3 (0.30)
SCHEMBL29496847 0.72 RAB9A (0.71) CTSVCTSLKDM4EHPGDLMNA
SCHEMBL2061664 0.72 RAB9A (0.71) CTSVCTSLKDM4EHPGDLMNA
SCHEMBL694914 0.70 CTSV (0.50) CTSVCTSLKDM4EHPGDLMNA
SCHEMBL695264 0.69 CTSV (0.49) CTSVCTSLKDM4EHPGDLMNA
SCHEMBL694967 0.68 CTSV (0.44) CTSVCTSLKDM4EHPGDLMNA
SCHEMBL695386 0.68 CYP1A1 (0.45) CTSVCTSLKDM4EHPGDLMNA
SCHEMBL934168 0.67 CYP1A2 (0.41) KDM4EHPGDLMNAALDH1A1MAPT
SCHEMBL1816734 0.67
SCHEMBL10968356 0.67 DAO (0.30)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2421825-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS Janssen Pharmaceutica N.V. (BE) 2012-02-29 EP claimed
WO-2010124108-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2010-10-28 WO claimed
EP-3197450-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF FIBROSIS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2017-08-02 EP disclosed
WO-2016046130-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF FIBROSIS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2016-03-31 WO disclosed